ADVERTISEMENT

Advanced NSCLC: public funding for immuno-oncology therapy tied to OS boost

Miriam Davis, PhD   |   Clinical Summary   |   18 March 2022
ADVERTISEMENT

Takeaway

  • The introduction of public reimbursement of immuno-oncology (I-O) therapies in Alberta, Canada, led to greater adoption of these therapies for advanced NSCLC and an increase in OS, according to real-world population-based data.

Why this matters

  • The findings contribute to the body of evidence of real-world benefits of I-O therapies for...

          

January Challenge

Ends in 2d 14h
left
right

Topic Challenges

left
right